scispace - formally typeset
M

Melinda E. Sanders

Researcher at Vanderbilt University Medical Center

Publications -  175
Citations -  21719

Melinda E. Sanders is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 56, co-authored 159 publications receiving 16095 citations. Previous affiliations of Melinda E. Sanders include Boston University & The Breast Cancer Research Foundation.

Papers
More filters
Journal ArticleDOI

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

TL;DR: Gen expression profiles from 21 breast cancer data sets and identified 587 TNBC cases may be useful in biomarker selection, drug discovery, and clinical trial design that will enable alignment of TNBC patients to appropriate targeted therapies.
Journal ArticleDOI

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

TL;DR: The most relevant molecular findings in TNBC from the past decade are discussed and the most promising therapeutic opportunities derived from these data are discussed.
Journal ArticleDOI

Proteogenomic characterization of human colon and rectal cancer

Bing Zhang, +64 more
- 18 Sep 2014 - 
TL;DR: Integrated proteogenomic analysis provides functional context to interpret genomic abnormalities and affords a new paradigm for understanding cancer biology.
Journal ArticleDOI

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

TL;DR: Pre-clinical data is provided that could inform clinical trials designed to test the hypothesis that improved outcomes can be achieved for TNBC patients, if selection and combination of existing chemotherapies is directed by knowledge of molecular TNBC subtypes.
Journal ArticleDOI

Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer

TL;DR: A view of how the somatic genome drives the cancer proteome and associations between protein and post-translational modification levels and clinical outcomes in HGSC is provided.